27 July 2026
27 July 2026
Preliminary trial data showed a 100% en bloc resection and conversion-free rate.
The move to the dose-expansion cohort follows earlier findings from the dose-escalation stage.
The combined formulation begins working in under 30 minutes and delivers pain relief for up to 12 hours.
The study aims to assess the safety, efficacy and device performance of the Venus-PowerX in severe aortic stenosis patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
